MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.